Immune checkpoint inhibitors and irAEs

Fukumi Furukawa

Article ID: 930
Vol 2, Issue 1, 2018

VIEWS - 999 (Abstract)

Keywords


immune checkpoint inhibitor; PD-1; CTLA-4; immune-related adverse events

Full Text:

PDF


References


1. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11(2): 141–151. doi: 10.1016/S1074-7613(00)80089-8.

2. Okazaki T, Honjo T. PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 2007; 19(7): 813–824. doi: 10.1093/intimm/dxm057.

3. Seidel JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and limitations. Trends Immunother 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20.

4. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends Immunother 2018; 2(2). doi: 10.24294/ti.v2.i2.606.

5. Fujimura T, Sato Y, Tanita K, et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget 2018; 9(21): 15542–15551. doi: 10.18632/oncotarget.24509.




DOI: https://doi.org/10.24294/ti.v2.i2.930

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Fukumi Furukawa

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.